Skip to main content
CMEducation Resources ScrollCall
  • menu
  • menu
  • person
  • Search
  • Specialty
  • Cardiology chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Specialty
  • Diabetes chevron_right

  • Specialty Program
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Glycemic Regulation chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • Specialty Program
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Cytokine Immunotherapy chevron_right
  • Hypothyroidism chevron_right
  • Specialty Program
  • Parkinson's Diseasechevron_right
  • Specialty
  • Cancer chevron_right

  • Specialty Program
  • Cytokine Immunotherapy chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Pain Management chevron_right
  • Specialty
  • Primary Care chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Congenital Adrenal Hyperplasia (CAH) chevron_right
  • Fabry Disease chevron_right
  • Hypothyroidism chevron_right
  • Pain Management chevron_right
  • Parkinson's Diseasechevron_right
  • Glycemic Regulation chevron_right
  • Specialty
  • Dermatology chevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Extracorporeal Photopheresis (ECP) chevron_right
  • Specialty
  • Biologicschevron_right

  • Specialty Program
  • Atopic Dermatitischevron_right
  • Cytokine Immunotherapy chevron_right
  • Fabry Disease chevron_right
  • Biosimilars for RA chevron_right
  • PCSK9s in Interventional Cardiology chevron_right
  • PCSK9s in Medical Preventative chevron_right
  • PCSK9s in Lipid Medicine & Atherosclerosis Prevention chevron_right
  • PCSK9s in Diabetes Management chevron_right
  • PCSK9s: A Multi-Specialty Perspective chevron_right
  • Fabry Disease chevron_right
  • Specialty
  • MAC Lung Disease chevron_right

  • Specialty Program
  • MAC Lung Disease chevron_right
    • close
    CMEducation Resources iQ&A
    • person
    • Home
    • Access All Programs
    • Specialtieschevron_right
      • chevron_leftTopics
      • Cardiology
      • Diabetes
      • Endocrinology
      • Neurology
      • Cancer
      • Primary Care
      • Dermatology
      • Biologics
      • MAC Lung Disease
    • Submit A Question
    close

    Hubert Fernandez, MD

    Hubert Fernandez, MD

    Center for Neurological Restoration
    Professor of Medicine (Neurology)
    Cleveland Clinic Lerner College of Medicine
    Case Western Reserve University
    Neurological Institute, Cleveland Clinic
    Cleveland, Ohio


    Related Videos

    Once you are confident with the diagnosis of PD, and you determine that pharmacologic therapy is warranted, what kind of clinical decision tree do you rely on to determine your initial, individualized choice for treatment? Video

    Once you are confident with the diagnosis of PD, and you determine that pharmacologic therapy is warranted, what kind of clinical decision tree do you rely on to determine your initial, individualized choice for treatment?

    Once you are confident with the diagnosis of PD, and you determine that pharmacologic therapy is warranted, what kind of clinical decision tree do you rely on to determine your initial, individualized choice for treatment?

    Can you please provide us with a brief summary of what you plan to cover on today’s CME program and your assessment of unmet needs in the treatment of PD? Video

    Can you please provide us with a brief summary of what you plan to cover on today’s CME program and your assessment of unmet needs in the treatment of PD?

    Can you please provide us with a brief summary of what you plan to cover on today’s CME program and your assessment of unmet needs in the treatment of PD?

    "Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD? Video

    "Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD?

    "Off time” may vary in severity at different times during the day due to physical activity and other factors, does this support the need to have different dosing options available in the manner provided by a scored, fractionated formulation of CD/LD?

    Can you provide some background on the disease burden associated with Parkinson’s Disease, and the challenges of confirming the diagnosis and heterogeneity in clinical presentation? Video

    Can you provide some background on the disease burden associated with Parkinson’s Disease, and the challenges of confirming the diagnosis and heterogeneity in clinical presentation?

    Can you provide some background on the disease burden associated with Parkinson’s Disease, and the challenges of confirming the diagnosis and heterogeneity in clinical presentation?

    Given that CD/LD therapy for PD is highly individualized, what are possible advantages of longer-acting formulations of CD/LD and/or the availability of a scored, fractionable formulation of CD/LD highly amenable to titration? Video

    Given that CD/LD therapy for PD is highly individualized, what are possible advantages of longer-acting formulations of CD/LD and/or the availability of a scored, fractionable formulation of CD/LD highly amenable to titration?

    Given that CD/LD therapy for PD is highly individualized, what are possible advantages of longer-acting formulations of CD/LD and/or the availability of a scored, fractionable formulation of CD/LD highly amenable to titration by the patient or the physician?

    What are the canonical signs, symptoms and historical features of PD, and what criteria must be met to confirm the diagnosis and consider initiation of pharmacologic therapy? Video

    What are the canonical signs, symptoms and historical features of PD, and what criteria must be met to confirm the diagnosis and consider initiation of pharmacologic therapy?

    What are the canonical signs, symptoms and historical features of PD, and what criteria must be met to confirm the diagnosis and consider initiation of pharmacologic therapy?

    What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD? Video

    What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD?

    What minimal diagnostic criteria or clinical symptom severity do you feel is required to be actionable for pharmacologic treatment in a person presenting with a sign-symptom complex suggestive of PD?

    Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration of motor symptoms over time? Video

    Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration of motor symptoms over time?

    Once you commit to carbidopa/levodopa therapy, what is the typical starting dose, how long does it take for symptoms to ameliorate, and what should you expect in terms of long-term stability and/or deterioration (adverse fluctuations of ...

    Disclaimer:
    Copyright © by CMEducation Resources, LLC All rights reserved. Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.
    Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.
    Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.
    Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.

    Clinical Webcasts®

    Powered by BroadcastMedBROADCASTMED